BioXcel Therapeutics (BTAI) Non-Current Debt (2022 - 2026)

BioXcel Therapeutics' Non-Current Debt history runs 5 years deep, the most recent figure standing at $77.9 million for Q1 2026.

• On a quarterly basis, Non-Current Debt fell 22.08% year-over-year to $77.9 million in Q1 2026; TTM through Mar 2026 was $77.9 million, a 22.08% decrease from a year earlier, with the FY2025 full-year figure at $84.7 million, down 17.41% from the prior year.
• Non-Current Debt eased to $77.9 million in Q1 2026 per BTAI's latest filing, from $84.7 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $104.4 million in Q3 2024 and bottomed at $61.1 million in Q2 2022.
• The 5-year median for Non-Current Debt is $97.2 million (2023), against an average of $93.8 million.
• Across the five-year window, Non-Current Debt jumped 58.57% in 2023 and slipped 22.08% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $93.1 million in 2022, then advanced by 8.11% to $100.6 million in 2023, then increased by 1.9% to $102.5 million in 2024, then fell by 17.41% to $84.7 million in 2025, then dropped by 8.04% to $77.9 million in 2026.
• Per Business Quant, the three latest BTAI Non-Current Debt figures stand at $77.9 million (Q1 2026), $84.7 million (Q4 2025), and $92.3 million (Q3 2025).